Pharmaceutical Executive September 13, 2023
We have entered a new reality in healthcare.
The recent announcement of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act (IRA) is an act of commitment by the current administration in its pursuit of drug reform—even in the face of litigation. In light of these changes and their implications, pharmaceutical manufacturers will need to rethink their launch strategies to ensure they are well positioned for the future.
While the IRA was passed in the spirit of creating a sustainable healthcare system by reducing the burden of drug cost on patients and the government, we cannot overlook the profound consequences it will have on the development and commercialization of new therapies. The provisions allowing Medicare to...
Today's Sponsors
Today's Sponsor